

| [Number of birth doses administered](concepts.html#number-of-birth-doses-administered) | [Age in Months](concepts.html#age-in-months) | [Number of weeks since last dose](concepts.html#number-of-weeks-since-last-dose) | [Number of doses administered](concepts.html#number-of-doses-administered) | [HIV status](concepts.html#hiv-status) | [Patient is currently receiving ART](concepts.html#patient-is-currently-receiving-art) | [Patient is currently pregnant](concepts.html#patient-is-currently-pregnant) | [Immune reconstitution was achieved](concepts.html#immune-reconstitution-was-achieved) | [CD4+ T Lymphocyte monitoring is available](concepts.html#cd4+-t-lymphocyte-monitoring-is-available) | [Number of months since HAART was initiated](concepts.html#number-of-months-since-haart-was-initiated) | [Current vaccination status](concepts.html#current-vaccination-status) | Decision | Annotation |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 0 | >6 and <9 | N/A | N/A | Positive | FALSE | N/A | N/A | N/A | N/A | No doses | Should vaccinate patient for measles (supplimentary) | [See note 1](#note1) |
| 0 | >=9 | N/A | 0 | N/A | N/A | FALSE | N/A | N/A | N/A | No doses | Should vaccinate patient for measles | [See note 2](#note2) |
| 0 | >=12 | N/A | 0 | N/A | N/A | FALSE | N/A | N/A | N/A | No doses | Should vaccinate patient for measles | [See note 3](#note3) |
| 1 | >=15 | >=4 | 1 | N/A | N/A | FALSE | N/A | N/A | N/A | 1 Dose | Should vaccinate patient for measles | N/A |
| N/A | N/A | N/A | N/A | Positive | TRUE | FALSE | TRUE | N/A | N/A | Supplimentary | Should vaccinate patient for measles supplimentary dose | [See note 4](#note4) |
| N/A | N/A | N/A | N/A | Positive | TRUE | FALSE | N/A | FALSE | >=6 and <=12 | Supplimentary | Should vaccinate patient for measles supplimentary dose | N/A |
{:.table-bordered .table-sm} 

<a name="note1"></a> Note 1: Refer to the first note in the CSV data for specifics on the supplementary dose.  
<a name="note2"></a> Note 2: This dose is applicable if the patient is in a setting where there is high transmission of Measles.  
<a name="note3"></a> Note 3: This dose is applicable if the patient is in a setting where there is low transmission of Measles.  
<a name="note4"></a> Note 4: This dose is applicable if immune reconstitution was achieved for the individual following HAART.
